Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Translational Research

Single-Nucleotide Polymorphisms and Cancer Risk, Tumor Recurrence, or Survival of Head and Neck Cancer Patients

Laytragoon-Lewin N.a, c · Cederblad L.i · Andersson B.-Å.a, c · Olin M.d · Nilsson M.e · Rutqvist L.E.f · Lundgren J.g · Engström M.h · Tytor W.b · Löfgren S.a · Lewin F.d

Author affiliations

aDepartment of Clinical and Experimental Medicine, Linköping University, and bDepartment of ENT, Linköping University Hospital, Linköping, cDivision of Medical Diagnostics, dDepartment of Oncology and eFuturum, Ryhov Hospital, Jönköping, fSwedish Match AB, and gDepartment of ENT, Karolinska University Hospital, Stockholm, and Departments of hENT and iOncology, Uppsala University Hospital, Uppsala, Sweden

Related Articles for ""

Oncology 2017;92:161-169

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Translational Research

Received: June 29, 2016
Accepted: September 19, 2016
Published online: December 21, 2016
Issue release date: March 2017

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Objective: This paper aims at studying the influence of single-nucleotide polymorphisms (SNPs) on cancer risk, tumor recurrence, and survival in head and neck (H&N) cancer patients. Methods: A total of 45 SNPs in 41 genes were investigated. A total of 174 Caucasian H&N cancer patients and 245 healthy blood donors were enrolled in the study. Results: Ten SNPs were associated with H&N cancer risk, but the identified SNPs differed among males and females. Some of the SNPs were related to immune response genes. The immune response gene SNPs were also related to survival. In particular, we noted that the tumor necrosis factor alpha (TNFα) rs1800629 could have an influence on cancer risk, tumor recurrence as well as survival. Conclusion: Genetic variation of the TNFα rs1800629 might be useful as a biomarker in clinical decision-making since it was found to be related to cancer risk, tumor recurrence, and survival of H&N cancer patients.

© 2016 S. Karger AG, Basel


References

  1. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, Rutqvist LE: Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998;82:1367-1375.
  2. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, Wan H, Waseem A, Parkinson EK, Fortune F, Teh MT: Foxm1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PloS One 2009;4:e4849.
  3. Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, Chen Q, Brandwein-Gensler M, Prystowsky MB, Childs G, Smith RV, Belbin TJ: Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007;213:283-293.
  4. Liu Z, Fang F, Chang ET, Ye W: Cancer risk in the relatives of patients with nasopharyngeal carcinoma - a register-based cohort study in Sweden. Br J Cancer 2015;112:1827-1831.
  5. Bennett WP, Alavanja MC, Blomeke B, Vahakangas KH, Castren K, Welsh JA, Bowman ED, Khan MA, Flieder DB, Harris CC: Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 1999;91:2009-2014.
  6. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA: Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996;313:716-721.
  7. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-311.
  8. Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW: Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med 2008;37:271-277.
  9. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: P53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005;11:7328-7333.
  10. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, Trichopoulos D, Ahrens W, Pigeot I, Merletti F, Richiardi L, Talamini R, Barzan L, Macfarlane GJ, Macfarlane TV, Holcatova I, Bencko V, Benhamou S, Bouchardy C, Kjaerheim K, Lowry R, Agudo A, Castellsague X, Conway DI, McKinney PA, Znaor A, McCartan BE, Healy CM, Marron M, Brennan P: Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res 2009;69:2956-2965.
  11. Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D: Polymorphism in cytochrome p450 2a6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res 2009;669:36-41.
  12. Andersson BA, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, Lofgren S, Laytragoon-Lewin N: Plasma tumor necrosis factor-alpha and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2014;140:515-519.
  13. Laytragoon-Lewin N, Jonson F, Lundgren J, Rutqvist LE, Wikby A, Lofgren S, Lewin F: Perforin, CD28 and CD95 expression in circulating CD4 and CD8 cells as predictors of head and neck (H&N) cancer patient survival. Med Oncol 2014;31:290.
  14. Cederblad L, Thunberg U, Engstrom M, Castro J, Rutqvist LE, Laytragoon-Lewin N: The combined effects of single-nucleotide polymorphisms, tobacco products, and ethanol on normal resting blood mononuclear cells. Nicotine Tob Res 2013;15:890-895.
  15. Supic G, Kozomara R, Brankovic-Magic M, Jovic N, Magic Z: Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncology 2009;45:1051-1057.
  16. Huang Y, Gu X: A bootstrap based analysis pipeline for efficient classification of phylogenetically related animal miRNAs. BMC Genomics 2007;8:66.
  17. Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL: Whole-genome genotyping with the single-base extension assay. Nat Methods 2006;3:31-33.
  18. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA: Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-731.
  19. Laytragoon-Lewin N, Chen F, Castro J, Elmberger G, Rutqvist LE, Lewin F, Turesson I, Lundgren J: DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients. Anticancer Res 2010;30:4643-4648.
  20. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR, Xu H, Schilling AB, Weber C, Ye RD, Dinner AR, Tang WJ: Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J 2010;29:3952-3966.
  21. Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, Hareyama M, Sugita T, Mitsuhashi N, Yamashita T, Aoki M, Sai H, Hirokawa Y, Sakata K, Karasawa K, Tomida A, Tsuruo T, Miki Y, Noda T, Hiraoka M: IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 2008;14:6683-6689.
  22. Yang L, Hu X, Xu L: Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012;33:1445-1454.
  23. Huang HY, Thuita L, Strickland P, Hoffman SC, Comstock GW, Helzlsouer KJ: Frequencies of single nucleotide polymorphisms in genes regulating inflammatory responses in a community-based population. BMC Genet 2007;8:7.
  24. Kruse AL, Bredell M, Luebbers HT, Gratz KW: Head and neck cancer in the elderly: a retrospective study over 10 years (1999-2008). Head Neck Oncol 2010;2:25.
  25. Laytragoon-Lewin N, Bahram F, Rutqvist LE, Turesson I, Lewin F: Direct effects of pure nicotine, cigarette smoke extract, swedish-type smokeless tobacco (Snus) extract and ethanol on human normal endothelial cells and fibroblasts. Anticancer Res 2011;31:1527-1534.
  26. Zhang N, Ma ZP, Wang J, Bai HL, Li YX, Sun Q, Yang L, Tao L, Zhao J, Cao YW, Li F, Zhang WJ: Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and Il-17 expression in patients with breast cancer. Am J Transl Res 2016;8:3214-3226.
  27. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
  28. de Vries M, Heijink IH, Gras R, den Boef LE, Reinders-Luinge M, Pouwels SD, Hylkema MN, van der Toorn M, Brouwer U, van Oosterhout AJ, Nawijn MC: Pim1 kinase protects airway epithelial cells from cigarette smoke-induced damage and airway inflammation. Am J Physiol Lung Cell Mol Physiol 2014;307:L240-L251.
  29. Heijink IH, Pouwels SD, Leijendekker C, de Bruin HG, Zijlstra GJ, van der Vaart H, ten Hacken NH, van Oosterhout AJ, Nawijn MC, van der Toorn M: Cigarette smoke-induced damage-associated molecular pattern release from necrotic neutrophils triggers proinflammatory mediator release. Am J Respir Cell Mol Biol 2015;52:554-562.
  30. Sin JI, Kim JM, Bae SH, Lee IH, Park JS, Ryoo HM: Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009;17:906-913.
  31. He J, Li X, Tang J, Jin T, Liao Q, Hu G: Association between chemotactic chemokine ligand 5 -403G/A polymorphism and risk of human immunodeficiency virus-1 infection: a meta-analysis. Onco Targets Ther 2015;8:727-734.
  32. Laytragoon-Lewin N, Porwit-MacDonald A, Mellstedt H, Lewin F: Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance. Anticancer Res 2000;20:1093-1100.
  33. Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M: Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 2015;21:312-321.
  34. Laytragoon-Lewin N, Rutqvist LE, Lewin F: DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: new diagnostic approaches and treatment. Med Oncol 2013;30:654.
  35. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-141.

Article / Publication Details

First-Page Preview
Abstract of Clinical Translational Research

Received: June 29, 2016
Accepted: September 19, 2016
Published online: December 21, 2016
Issue release date: March 2017

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.